Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Patients
Investors + Media

>> Sub navigation

Careers
Contact

Investors + Media: Press Releases

Press Releases

Year

December 10, 2021

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

November 19, 2021

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

November 10, 2021

Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

November 3, 2021

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

September 1, 2021

Arvinas to Participate in Upcoming Virtual Investor Conferences

August 5, 2021

Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

July 22, 2021

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

June 7, 2021

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

June 3, 2021

Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference

May 20, 2021

Arvinas to Present at the UBS Global Healthcare Virtual Conference

Pagination

Current page 1
Page 2
Next page
Last page

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2022. All Rights Reserved.

Contact Privacy Policy Terms & Conditions